{"nctId":"NCT03444324","briefTitle":"Adjusted Fibrinogen Replacement Strategy","startDateStruct":{"date":"2018-04-03","type":"ACTUAL"},"conditions":["Bleeding Disorder","Hypofibrinogenemia; Acquired"],"count":222,"armGroups":[{"label":"BT524","type":"EXPERIMENTAL","interventionNames":["Biological: BT524"]},{"label":"Fresh Frozen Plasma (FFP)/Cryoprecipitate (Cryo)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: FFP/Cryo"]}],"interventions":[{"name":"BT524","otherNames":["Human Fibrinogen concentrate"]},{"name":"FFP/Cryo","otherNames":["Fresh Frozen Plasma","Cryoprecipitate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nAt screening:\n\n1. Written informed consent\n2. Subjects scheduled for elective major spinal surgery or cytoreductive pseudomyxoma peritonei (PMP) surgery with expected major blood loss\n3. Male or female, aged â‰¥ 18 years\n4. No increased bleeding risk as assessed by standard coagulation tests and medical history\n\nIntra-operative:\n\n5\\.\n\n1. Subjects who underwent spinal surgery: Intra-operative clinically relevant bleeding of approximately 1 Liter, requiring hemostatic treatment during surgery.\n2. Subjects who underwent cytoreductive PMP surgery: Intra-operative prediction of clinically relevant bleeding of more than 2 Liter, requiring hemostatic treatment during surgery\n\nExclusion Criteria:\n\n1. Pregnancy or unreliable contraceptive measures or breast feeding (women only)\n2. Hypersensitivity to proteins of human origin or known hypersensitivity reactions to components of the Investigational Medicinal Products (IMP)\n3. Participation in another clinical study within 30 days before entering the study or during the study and/or previous participation in this study\n4. Treatment with any fibrinogen concentrate and/or fibrinogen-containing product within 30 days prior to infusion of IMP\n5. Employee or direct relative of an employee of the Contract Research Organization (CRO), the study site, or Biotest\n6. Inability or lacking motivation to participate in the study\n7. Medical condition, laboratory finding (e.g., clinically relevant biochemical or hematological findings outside the normal range), or physical exam finding that in the opinion of the investigator precludes participation\n8. Presence or history of venous/arterial thrombosis or thromboembolic event (TEE) in the preceding 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Intra-operative Blood Loss","description":"Intra-operative blood loss as measured by amount of blood from blood suction unit and amount of blood from surgical cloths and compresses.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1380.7","spread":null},{"groupId":"OG001","value":"1660.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion (%) of Subjects With Successful Correction of Fibrinogen Level (FIBTEM A10) 15 Minutes After Start of First IMP Administration","description":"Successful correction of the fibrinogen level is defined as restoring fibrinogen FIBTEM A10 baseline (prior surgery) levels measured by ROTEM (thromboelastometry) 15 minutes after start of first IMP administration","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Successful Correction of Fibrinogen Level","description":"Correction of the fibrinogen level, measured via thromboelastometry (ROTEM/FIBTEM A10), within 15 minutes after IMP start, between 15 and 90 minutes after IMP start, after 90 minutes after IMP start, or unsuccessful correction. The 4 categories were compared between the two treatment arms using a Chi-square test.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]}]},{"type":"SECONDARY","title":"Transfusion Requirements: Cell Salvage","description":"Total amount of transfusion products (allogeneic blood products) or autologous blood transfusion infused after start of first IMP administration until end of surgery. The end of surgery is defined as time of last suture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.6","spread":"244.57"},{"groupId":"OG001","value":"78.0","spread":"234.77"}]}]}]},{"type":"SECONDARY","title":"Transfusion Requirements: Allogeneic Platelets","description":"Total amount of transfusion products (allogeneic blood products) or autologous blood transfusion infused after start of first IMP administration until end of surgery. The end of surgery is defined as time of last suture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"30.94"},{"groupId":"OG001","value":"3.6","spread":"36.38"}]}]}]},{"type":"SECONDARY","title":"Transfusion Requirements: Allogeneic Red Blood Cells","description":"Total amount of transfusion products (allogeneic blood products) or autologous blood transfusion infused after start of first IMP administration until end of surgery. The end of surgery is defined as time of last suture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"455.5","spread":"492.19"},{"groupId":"OG001","value":"488.4","spread":"547.72"}]}]}]},{"type":"SECONDARY","title":"Transfusion Requirements: Fresh Frozen Plasma","description":"Total amount of transfusion products (allogeneic blood products) or autologous blood transfusion infused after start of first IMP administration until end of surgery. The end of surgery is defined as time of last suture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":"217.68"},{"groupId":"OG001","value":"14.8","spread":"110.94"}]}]}]},{"type":"SECONDARY","title":"Transfusion Requirements, Cryoprecipitate","description":"Total amount of transfusion products (allogeneic blood products) or autologous blood transfusion infused after start of first IMP administration until end of surgery. The end of surgery is defined as time of last suture.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":"0"},{"groupId":"OG001","value":"0","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Amount of Red Blood Cells (RBCs)","description":"Amount (volume) of RBCs (allogenic and autologous RBCs) infused after start of first IMP administration until end of surgery. The end of surgery is defined as time of last suture.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"543.4","spread":null},{"groupId":"OG001","value":"558.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-operative Blood Loss","description":"Post-operative drainage volume in the first 24 hours after end of surgery","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306.3","spread":null},{"groupId":"OG001","value":"293.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects With Rebleeds","description":"Proportion (%) of subjects with rebleeds after the end of surgery until day 8","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospital Length of Stay After Surgery","description":"Length of stay after surgery (days) = 'date of hospital discharge' minus 'date of surgery'. Where date of discharge is the date of discharge following the IMP treated surgery.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]},{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"49","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"In-hospital Mortality","description":"Number and percentages of subjects who died during hospital stay","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Thrombosis or Thromboembolic Events (TEEs)","description":"Total number of subjects with thrombosis or TEEs documented as treatment-emergent adverse events of special interest","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Viral Status","description":"Number of subjects with change in status of viral infections","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":110},"commonTop":["Hallucination","Hypotension","Tachycardia","Hypertransaminasaemia","Anaemia postoperative"]}}}